Curis’ (CRIS) Buy Rating Reiterated at HC Wainwright

Curis (NASDAQ:CRIS)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $20.00 target price on the biotechnology company’s stock. HC Wainwright’s price target suggests a potential upside of 398.75% from the stock’s previous close.

Curis Stock Up 0.8 %

CRIS stock traded up $0.03 during mid-day trading on Friday, reaching $4.01. 77,075 shares of the stock traded hands, compared to its average volume of 40,062. The firm has a market capitalization of $23.98 million, a PE ratio of -0.49 and a beta of 3.35. The business has a 50-day moving average of $5.06 and a two-hundred day moving average of $7.21. Curis has a 52 week low of $3.51 and a 52 week high of $17.49.

Institutional Investors Weigh In On Curis

Large investors have recently bought and sold shares of the business. Focused Wealth Management Inc raised its position in Curis by 63.1% in the 3rd quarter. Focused Wealth Management Inc now owns 54,066 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 20,908 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Curis by 795.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 108,356 shares of the biotechnology company’s stock valued at $748,000 after buying an additional 96,256 shares during the last quarter. CM Management LLC increased its stake in shares of Curis by 380.0% in the 1st quarter. CM Management LLC now owns 120,000 shares of the biotechnology company’s stock valued at $1,304,000 after buying an additional 95,000 shares during the period. Finally, Vanguard Group Inc. raised its position in shares of Curis by 4.8% during the first quarter. Vanguard Group Inc. now owns 218,573 shares of the biotechnology company’s stock worth $2,376,000 after acquiring an additional 10,097 shares during the last quarter. 29.97% of the stock is currently owned by institutional investors.

About Curis

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes.